Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
The Use of Oral Disease-Modifying Therapies in Multiple Sclerosis.
Impact of cost sharing on specialty drug utilization and outcomes: a review of the evidence and future directions.
Closing the quality gap: revisiting the state of the science (vol. 4: medication adherence interventions: comparative effectiveness).
Exploring potential mechanisms of action of natalizumab in secondary progressive multiple sclerosis.
Perceived cognitive decline in multiple sclerosis impacts quality of life independently of depression.
cFLIP is critical for oligodendrocyte protection from inflammation.
Production and use of lentivirus to selectively transduce primary oligodendrocyte precursor cells for in vitro myelination assays.
MCAM(+) CD8 T lymphocytes mediate CNS inflammation.
Knee muscle strength in multiple sclerosis: relationship with gait characteristics.
The Parallel Analysis of Phase Sensitive Inversion Recovery (PSIR) and Double Inversion Recovery (DIR) Images Significantly Improves the Detection of Cortical Lesions in Multiple Sclerosis (MS) since Clinical Onset.
Mitochondrial mutations of Leber's hereditary optic neuropathy: a risk factor for multiple sclerosis.
The synthetic NCAM mimetic peptide FGL mobilizes neural stem cells in vitro and in vivo.
Evidence for a multiple sclerosis epidemic?
Safety of disease-modifying drugs for multiple sclerosis in pregnancy: current challenges and future considerations for effective pharmacovigilance.
Characterization of the first K(+) channel blockers from the venom of the Moroccan scorpion Buthus occitanus Paris.
[NMO Spectrum Disorders and Anti AQP4 Antibody].
The Standards of Reporting of Neurological Disorders (STROND) checklist: Application to multiple sclerosis.
Nonallergic comorbidities of atopic eczema: an overview of systematic reviews.
Antibody index test may aid PML diagnosis on natalizumab
[Cognitive deficits and dementia in patients with multiple sclerosis: status quo and open questions].
The Effect of a Creative Art Program on Self-Esteem, Hope, Perceived Social Support, and Self-Efficacy in Individuals With Multiple Sclerosis: A Pilot Study.
Analysis of polymorphisms in RIG-I-like receptor genes in German multiple sclerosis patients.
Free radicals: properties, sources, targets, and their implication in various diseases.
Activity-dependent regulation of excitable axonal domains.
Neuropsychiatric systemic lupus erythematosus persists despite attenuation of systemic disease in MRL/lpr mice.
Pages
« first
‹ previous
…
383
384
385
386
387
388
389
390
391
…
next ›
last »